Intellectual Property and Litigation
13th Summit on Biosimilars & Innovator Biologics
Event summary
The 13th Summit on Biosimilars & Innovator Biologics will discuss hot industry topics, including the rules governing significant matters like interchangeability, substitution and equivalency. Speakers will include representatives of government agencies, industry leaders and seasoned counsel.
For more information, please email Maria Russo.
Featured agenda item
Balancing Innovation and Competition: Patent Thickets, Continued Litigation and New Economic Considerations for Settlements
Wednesday, June 29, 2022: 10:30 – 11:30 am ET
Cooley partner Orion Armon is a featured speaker.
Antitrust enforcement is routinely triggered via the approval of a biosimilar. Many believe that anti-competitive behavior exhibited by reference products represents the most formidable barrier to entry. In response, FDA and FTC recently issued a joint statement regarding a collaboration to advance competition in the biologic marketplace. Complicating matters further, several states have enacted laws meant to curb reverse-payment patent settlements – with no comparable statute at the federal level. This session will consider the economic implications of biosimilar reverse payment litigation, the competitive effects and economic damages.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.